These Surging Divvies Are the Next AI Winners (Wall Street Hates Them)

The note pitches two income-oriented plays tied to an anticipated AI-driven acceleration in drug discovery: Becton, Dickinson & Co. (BDX) and the BlackRock Health Sciences closed-end fund (BME). AI is argued to cut drug-development timelines materially, boosting demand for lab and diagnostic equipment — a tailwind for BDX’s Life Sciences franchise; BDX is also combining bioscience and diagnostics assets with Waters Corp., creating a larger, faster-growth $40bn market opportunity, and will receive $4bn cash at close (around end-Q1) with roughly half earmarked for buybacks and the remainder for debt reduction, supporting its 2.8% payout that currently represents about 45% of free cash flow. BME offers a 7.8% monthly dividend, is diversified across medical-device and biotech names (ABBV, TMO, BSX, etc.), and trades at an ~8% discount to NAV versus a 5‑year average of 2.9%, presenting potential for NAV compression gains plus yield if AI-driven sector re-rating materializes.

Analysis

The author advances an AI-driven re-rating of healthcare where machine learning could materially shorten drug discovery timelines (from about 10–15 years toward ~6 years) and reduce the ~$2.5 billion development cost cited, increasing addressable demand for lab, diagnostic and specimen‑collection equipment. The note also highlights regulatory context—insulin caps, the Inflation Reduction Act’s pricing limits (flagged as a potential ~$160 billion profit hit on 10 blockbusters) and subsequent industry concessions that yielded faster FDA reviews and more predictable reimbursement—factors that temper but do not negate the AI upside.

Becton, Dickinson & Co. (BDX) is presented as a cheap pick-and-shovel beneficiary: its hospital staples and Life Sciences portfolio should gain from higher research throughput, and the planned merger of its bioscience and diagnostics assets with Waters (WAT) targets a doubled market to $40 billion and 5%–7% annual growth. BDX shareholders would hold 39.2% of the merged business; BDX will receive $4 billion cash at close (around end‑Q1) and intends to use roughly half for buybacks and half for debt reduction, supporting its 2.8% yield which represents ~45% of free cash flow despite a post‑May earnings selloff.

The BlackRock Health Sciences Fund (BME) offers a 7.8% monthly dividend and currently trades at an ~8% discount to NAV versus a five‑year average of 2.9%, with top holdings including ABT, TMO and BSX and BDX at only 1.88% of assets. The fund structure can magnify returns if the sector re‑rates (discount compression) but also poses downside if discounts widen or dividend coverage deteriorates, so yield attractiveness must be balanced against CEF‑specific and regulatory risks.

Key Decisions for Investors

• Consider initiating a modest, sized position in BDX to capture the potential value unlocking from the Waters transaction and the $4 billion cash allocation (about $2 billion for buybacks) given a 2.8% yield funded at ~45% of FCF, but monitor integration execution and upcoming quarterly results for confirmation of the recovery
• Consider buying BME to lock in a 7.8% monthly yield and asymmetry from an ~8% discount-to-NAV if AI-driven device demand materializes, while sizing exposure conservatively and watching the fund's discount level, leverage and dividend sustainability
• Use near-term catalysts—Waters close (end‑Q1), BDX earnings cadence, early AI adoption metrics and any drug‑pricing regulatory moves—as rebalancing triggers and be prepared to trim or hedge positions if CEF discounts widen or regulatory headwinds re‑intensify